RxDoctor Payments Data

Darrell Triulzi

Pittsburgh, PANPI 1932175593

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,890,974 of the $2,908,398 with a category attached, or 99.4%. Vitalant accounts for 90.3% of it on its own, with 5 other manufacturers making up the rest.

$2,908,398in general payments, 2019–2025

Across 80 payments — averaging $36,355 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vitalant$2.6M
  • Institute For Transfusion Medicine$261K
  • Fresenius Kabi USA, LLC$17K
  • Terumo BCT, Inc.$3K
  • Werfen USA LLC$186
  • Cerus Corporation$74
$59,583in research payments, 2019–2025

Across 12 payments — averaging $4965.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Institute For Transfusion Medicine$60K

What the payments were for

  • Consulting fees$16,9341%
  • Speaking & faculty fees$2,890,97499%
  • Food & beverage$4030%
  • Gifts$860%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vitalant56$2,627,351
Institute For Transfusion Medicine5$260,823
Fresenius Kabi USA, LLC14$17,163
Terumo BCT, Inc.1$2,800
Werfen USA LLC2$186
Cerus Corporation2$74

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →